Directori de persones
Nuria Eritja Sanchez

Nuria Eritja Sanchez

Grau: Doctor/a

973 70 29 37
neritja(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/M-1347-2015

Publicacions

  • Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A

    M-CSF as a therapeutic target in BRAF(V600E) melanoma resistant to BRAF inhibitors.

    BRITISH JOURNAL OF CANCER 127 1142-1152. .

    [doi:10.1038/s41416-022-01886-4]

  • Ruiz-Mitjana A; Navaridas R; Vidal-Sabanés M; Perramon-Güell A; Yeramian A; Felip I; Eritja N; Egea J; Encinas M; Matias-Guiu X; Dolcet X

    Lack of extracellular matrix switches TGF-ß induced apoptosis of endometrial cells to epithelial to mesenchymal transition.

    SCIENTIFIC REPORTS 12 14821-14821. .

    [doi:10.1038/s41598-022-18976-1]

  • Gatius S; Jove M; Megino-Luque C; Albertí-Valls M; Yeramian A; Bonifaci N; Piñol M; Santacana M; Pradas I; Llobet-Navas D; Pamplona R; Matías-Guiu X; Eritja N

    Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.

    Cancers 14 -. .

    [doi:10.3390/cancers14122842]

  • Megino-Luque, C; Siso, P; Mota-Martorell, N; Navaridas, R; de la Rosa I; Urdanibia, I; Alberti-Valls, M; Santacana, M; Pinyol, M; Bonifaci, N; Macia, A; Llobet-Navas, D; Gatius, S; Matias-Guiu, X; Eritja, N

    ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.

    MOLECULAR ONCOLOGY 16 2235-2259. .

    [doi:10.1002/1878-0261.13193]

  • Eritja N; Navaridas R; Ruiz-Mitjana A; Vidal-Sabanés M; Egea J; Encinas M; Matias-Guiu X; Dolcet X

    Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation

    Cancers 13 -. .

    [doi:10.3390/cancers13194990]

  • Sanegre S; Eritja N; de Andrea C; Diaz-Martin J; Diaz-Lagares Á; Jácome MA; Salguero-Aranda C; García Ros D; Davidson B; Lopez R; Melero I; Navarro S; Ramon Y Cajal S; de Alava E; Matias-Guiu X; Noguera R

    Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma.

    Frontiers In Cell And Developmental Biology 9 670185-670185. .

    [doi:10.3389/fcell.2021.670185]

  • Megino-Luque C; Moiola CP; Molins-Escuder C; López-Gil C; Gil-Moreno A; Matias-Guiu X; Colas E; Eritja N

    Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

    Cancers 12 1-26. .

    [doi:10.3390/cancers12102751]

  • Cuevas, D; Velasco, A; Vaquero, M; Santacana, M; Gatius, S; Eritja, N; Estaran, E; Matias-Guiu, X

    Intratumor heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification (MLPA). A DESCRIPTIVE STUDY.

    Histopathology 76 447-460. .

    [doi:10.1111/his.14001]

  • Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet, X; Matias-Guiu, X; Marti, RM; Macia, A

    T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF V600E melanoma: TTCCs are therapy target in BRAF V600E melanoma.

    JOURNAL OF INVESTIGATIVE DERMATOLOGY 140 1253-1265. .

    [doi:10.1016/j.jid.2019.11.014]

  • Cuevas, D; Valls, J; Gatius, S; Roman-Canal, B; Estaran, E; Dorca, E; Santacana, M; Vaquero, M; Eritja, N; Velasco, A; Matias-Guiu, X

    Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma

    VIRCHOWS ARCHIV 474 585-598. .

    [doi:10.1007/s00428-018-02516-2]

  • Felip, I; Moiola, CP; Megino-Luque, C; Lopez-Gil, C; Cabrera, S; Sole-Sanchez, S; Muñoz-Guardiola P; Megias-Roda, E; Perez-Montoyo, H; Alfon, J; Yeste-Velasco, M; Santacana, M; Dolcet, X; Reques, A; Oaknin, A; Rodriguez-Freixinos, V; Lizcano, JM; Domènech C; Gil-Moreno, A; Matias-Guiu, X; Colas, E; Eritja, N

    Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer

    GYNECOLOGIC ONCOLOGY 153 425-435. .

    [doi:10.1016/j.ygyno.2019.03.002]

  • Dosil, MA; Navaridas, R; Mirantes, C; Tarragona, J; Eritja, N; Felip, I; Urdanibia, I; Megino, C; Domingo, M; Santacana, M; Gatius, S; Piñol C; Barcelo, C; Maiques, O; Macia, A; Velasco, A; Vaquero, M; Matias-Guiu, X; Dolcet, X

    Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis

    JOURNAL OF PATHOLOGY 247 72-85. .

    [doi:10.1002/path.5168]

Projectes

  • Papel de ARID1A en la carcinogénesis endometrial dependiente de contexto. Análisis de los mecanismos moleculares y posibles implicaciones terapéuticas
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • Contrato Miguel Servet - Proyecto
  • LYOTEK
  • "Determinación del perfil metabólico del carcinoma endometrioide de endometrio grado 3 para discriminar los subtipos tumorales establecidos por clasificación del TCGA (The Cancer Genome Atlas Research Network)"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment
  • Estudio de los efectos de la inhibición de la vía PI3K/AKT/mTOR en tumores deficientes en PTEN: mecanismos de resisitencia y nuevas estrategias terapéuticas
  • UNA FLOR PER A UN PROJECTE: ESTUDI DE DOS FARMACS PEL TRACTAMENT DEL MELANOMA